CME Presentations




  • Raymond Cross, M.D., M.S., A.G.A.F., F.A.C.G

    Raymond Cross, M.D., M.S., A.G.A.F., F.A.C.G

    Raymond Cross, M.D., M.S., A.G.A.F., F.A.C.G

    Professor of Medicine, Division of Gastroenterology and Hepatology

    Raymond Cross, M.D., M.S., A.G.A.F., F.A.C.G. is a Professor of Medicine, Division of Gastroenterology and Hepatology, at the University of Maryland, Baltimore. Also, he is Director of the Inflammatory Bowel Disease Program at the University of Maryland School of Medicine and Director of the Digestive Health Center at the University of Maryland Medical Center. Dr. Cross has authored over 170 journal articles, reviews, and book chapters. His research interests include application of telemedicine in the care of patients with IBD, disparities, outcomes research and clinical trials. Furthermore, Dr. Cross is Co-Chair of the Clinical Research Alliance, Research & Investigator Engagement Lead for SPARC IBD, and Scientific Co-Director of the Corevitas Registry.
  • Florence-Damilola Odufalu, MD

    Florence-Damilola Odufalu, MD

    Florence-Damilola Odufalu, MD

    Assistant Professor of Clinical Medicine

    Florence-Damilola Odufalu, MD is a passionate provider and clinical researcher in gastroenterology and inflammatory bowel diseases (IBD), including Crohn’s disease, ulcerative colitis, indeterminate colitis, and microscopic colitis. Her research and clinical interests include disparities research, women’s health, and pregnancy as each relates to IBD. Dr. Odufalu has published many ground-breaking research articles and reviews assessing IBD care in pregnancy and in ethnic minority groups and serves on the editorial board of Inflammatory Bowel Diseases Journal.

CME Information

Global LogoPQH Logo

Equity in UC Care: Listening to Patients and Integrating Novel Therapies to Induce and Maintain Remission

This activity is jointly provided by Partners for Advancing Clinical Education (PACE) and PlatformQ Health Education, LLC.


This activity is supported by an independent educational grant from Bristol Myers Squibb Company.


This activity was released on August 29, 2023 and is valid until August 29, 2024. Requests for credit must be made no later than August 29, 2024.


The target audience for this activity are gastroenterologists and NPs/PAs involved in management of patients with IBD.


Sphingosine-1-phosphate receptor (S1PR) modulators are a recently approved treatment option for patients with ulcerative colitis (UC). However, many patients who would benefit from these advances in treatment are not receiving them. Furthermore, patients from non-White racial and ethnic backgrounds experience worse outcomes from UC, and face barriers to care and treatment. Optimized management for UC necessitates an up-to-date understanding of the therapeutic landscape and an equitable approach to treatment decision-making and care

Join expert gastroenterologists, Florence-Damilola Odufalu, MD and Raymond Keith Cross Jr., MD, MS who will discuss the role of sphingosine-1-phosphate (S1P) receptor modulators in inducing and maintaining remission for patients with moderate-to-severe UC, provide guidance on how these therapies can be effectively integrated into management plans, and share strategies to address the unique challenges faced during the care of patients with UC across different races and ethnicities.


After completing this activity, the participant should be better able to:
  • Discuss the burden of UC with a focus on the impacts of race and ethnicity on UC prognosis and care access
  • Identify the role of S1P receptor modulators to induce and maintain remission of UC
  • Establish strategies to break down barriers to UC care access among people of various races and ethnicities


JointlyAccreditedProvider Logo In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and PlatformQ Health Education, LLC. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


PACE designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


This activity should take approximately 60 minutes to complete.


In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a score of 75% on the post-test.


Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.


There is no fee for this educational activity.


PACE requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Name of Faculty or Presenter Conflicts of Interest
Florence-Damilola Odufalu, MD
Assistant Professor of Clinical Medicine
Keck School of Medicine of University of Southern California
Consultant, Advisor, Speaker: Bristol-Myers-Squibb, Jansen, Pfizer
Raymond Keith Cross Jr., MD, MS
Professor of Medicine
Director of the IBD Program
University of Maryland School of Medicine
Consultant, Advisor, Speaker: Abbvie, Adiso, BMS, Fresenius Kabi, Fzata, Janssen, Magellan Health, Pfizer, Samsung Bioepis, Sebela
Executive Committee Member: IBD Education Group
Scientific Co-Director: CorEvitas
Keisha Parker
Vignette Participant
Patient with Ulcerative Colitis
No relevant financial relationships to disclose.

The PACE planners and others have no relevant financial relationship(s) to disclose with ineligible companies. The PlatformQ Health Education, LLC planners and others have no relevant financial relationship(s) to disclose with ineligible companies.


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Accreditation Support:

For additional information about the accreditation of this activity, please visit

Technical Support:

For any technical issues or issues with your CME Certificate, please contact ImmunologyLive at 877-394-1306 or at